Sanara Medtech Inc

Several biotech stocks posted sharp gains on Wednesday, led by SciSparc after its subsidiary completed internal validation of a quantum sampling platform for clinical trial data. SciSparc closed at $9.09, up 70.54%, following the announcement that NeuroThera Labs successfully validated the platform being advanced by CliniQuantum, in which NeuroThera holds a 54.01% ownership interest. Avantor rose 15.78% to $14.38 after reporting second-quarter net sales of $1.69 billion and raising its full-year adjusted EPS guidance to $0.80 to $0.83 from $0.77 to $0.83. NeoGenomics gained 13.96% to $15.27 after second-quarter consolidated revenue increased 11% to $202 million and the company lifted its full-year revenue outlook to $802 million to $806 million from $797 million to $803 million. Alvotech climbed 13.87% to $3.53 after the FDA classified the inspection of its Reykjavik manufacturing facility as Voluntary Action Indicated, a step forward for its biosimilar applications. Sanara MedTech surged 13.55% to $30.25 after agreeing to be acquired by MiMedx Group in a cash-and-stock deal valued at $35 per share, or about $350 million in total enterprise value. LB Pharmaceuticals advanced 11.62% to $39.00 after securing a $150 million private placement and accelerating the timeline for topline results from its Phase 3 schizophrenia trial to the first half of 2027.

MIMEDX announced second quarter 2026 net sales of $64 million, a 35% decline from the prior year, and separately unveiled a definitive agreement to acquire Sanara MedTech in a cash-and-stock deal valued at approximately $350 million. Surgical product sales grew 15% year-over-year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes that took effect on January 1. The company reported a net loss of $15 million for the quarter, compared to net income of $10 million a year earlier, and held $136 million in cash and equivalents as of June 30. MIMEDX reiterated its full-year 2026 net sales guidance of $260 to $290 million and expects Adjusted EBITDA to approach breakeven. Under the Sanara acquisition terms, Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MIMEDX common stock per share, representing a 46% premium to Sanara’s 30-day volume-weighted average price, with the transaction expected to close by year-end subject to shareholder and regulatory approvals.